Bristol-Myers Squibb is expanding its R&D capabilities in India by extending its relationship with Biocon and establishing a research facility in Bangalore.
Subscribe to our email newsletter
Bristol-Myers Squibb plans to work with India's leading biotech firm Biocon Limited to further its research in medicinal chemistry, biology, drug metabolism, and pharmaceuticals. Under the terms of the agreement, Biocon, through its subsidiary Syngene International, will work with BMS to establish a research facility that could house more than 400 scientists.
Accenture will provide support for clinical data and document management, pharmacovigilance, and scientific writing functions in India, BMS said. Accenture will also provide maintenance and support for R&D information systems.
“This broad expansion of R&D in India will allow us to grow competitively while maintaining our industry-leading position in productivity and innovation,” said Elliott Sigal, executive vice president for Bristol-Myers Squibb.